Transforming for Tomorrow: Xtant Medical's Strategic Evolution and Financial Growth

Q4 2025 Performance: A Look at Revenue and Profitability

Xtant Medical reported a solid financial performance for the fourth quarter of 2025, with revenue reaching $32.4 million, marking a 3% increase year-over-year from $31.5 million. This growth was achieved despite the early closing of the Companion Spine transaction, which impacted fourth-quarter revenue by approximately $2 million. The company's gross margin saw a notable improvement, rising to 54.9% from 50.8% in the previous year, driven primarily by a favorable sales mix and increased operational scale, partially offset by an inventory charge related to the Cortera fixation system launch.

Full-Year 2025 Financial Milestones and Strategic Divestiture

For the full fiscal year 2025, Xtant Medical reported total revenue of $133.9 million, aligning with the upper end of its guidance range. This represents a 14% increase from $117.3 million in 2024, showcasing strong overall growth. A pivotal moment for the company was the divestiture of its non-core Coflex interlaminar stabilization assets and International Paradigm Spine entities to Companion Spine for approximately $21.4 million. This strategic move allowed Xtant Medical to concentrate on its high-margin biologics business, use proceeds to reduce debt, and strengthen its cash position, eliminating the need for external capital in the near future.

Operational Expenses and Net Income Shift

Operating expenses for the fourth quarter totaled $18.7 million, a slight increase from $17.9 million in the prior year. General and administrative expenses rose to $7.3 million, mainly due to increased compensation plans, while sales and marketing expenses decreased to $10.9 million, reflecting lower commissions. Research and development expenses also saw a reduction. Critically, Xtant Medical achieved a net income of $57,000 in Q4, a significant turnaround from a net loss of $3.2 million in the year-ago quarter. For the full year, the company reported a net income of $5.0 million, reversing a net loss of $16.5 million in 2024.

Strengthening Financial Position and Capital Management

The company ended 2025 with a robust cash position, holding $17.3 million in cash, cash equivalents, and restricted cash, a substantial increase from $6.2 million a year earlier. This figure excludes an additional $10.7 million received post-year-end from Companion Spine. Xtant Medical also reported net accounts receivable of $17.8 million and inventory of $30.3 million, underscoring a healthy balance sheet and prudent financial management following its strategic adjustments.

Commercial Growth and Product Innovation Driving Future Prospects

With a solid financial foundation established, Xtant Medical is now prioritizing top-line growth. The company significantly expanded its regional sales force in 2025 and early 2026 and plans to invest further in its national accounts team to boost institutional adoption. Key product launches, such as nanOss Strata, a next-generation bone graft with enhanced bioactivity, and CollagenX, a bovine collagen particulate for surgical wound closure, are expected to be major growth drivers. These innovations aim to expand market opportunities across various surgical disciplines.

2026 Outlook: Navigating Transitions and Sustaining Growth

Xtant Medical provided a revenue guidance of $95 million to $99 million for full-year 2026. This projection accounts for the impact of the Companion Spine divestiture and the expiration of license revenues, which are considered non-recurring items. Despite these anticipated headwinds, the company expects sequential quarterly growth, driven by the increased productivity of its expanded commercial team and the traction gained by new products. Xtant Medical remains committed to maintaining positive free cash flow and foresees no need for additional external capital.